StockLens

Alkem Laboratories Limited (ALKEM) share price and analysis

ALKEM last traded at ₹5,175.00 (+0.76%) on the NSE. Market cap ₹61,875 Cr (Mid cap), Pharma & Healthcare sector.

Overall rating: 5.7/10 (Average)

Long-term view: Neutral (watchlist). A mixed picture. Wait for better value or a clearer trend. Trade bias (next few weeks): Strong short. Trend and momentum are clearly pointing down.

Strengths of ALKEM

Weaknesses of ALKEM

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)29.9Cheaper than peers37.0–49.3 (sector median 41.1)
Forward P/E23.4Profits expected to growbelow today's P/E (29.9) and near 41
Price / book4.16Normal2–6
EPS (TTM)₹172.93Profitableabove ₹0
Return on equity14.2%Average15%+ (below 10% is weak)
Debt / equity0.15Low debtbelow 1.0 (under 0.5 is great)
Net margin13.2%Healthy10%+ (below 5% is thin)
Operating margin17.1%Average20%+ strong, below 10% thin
Revenue growth+13.8%Growing well10%+ a year (below 3% is weak)
Profit growth-11.7%Falling10%+ a year (falling is weak)
Dividend yield0.39%Small payout1.5%+ (none is fine for growth firms)
Current ratio2.76Comfortable1.5+ (below 1 is tight)
52W high₹5,933.5013% below · far from the highprice in the top 40% of its 52-week range
52W low₹4,811.00Price is 8% above it
50-DMA₹5,201.03Price 0.5% belowprice above it = short-term uptrend
200-DMA₹5,414.65Price 4.4% belowprice above it = long-term uptrend
1Y return-8.7%Lagged the Nifty 50Nifty 50 did −0.4%
Beta0.29Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider61.4%Owners have a big stake50%+ shows owner commitment
Institutions28.6%Moderate interest30%+ is strong
Analyst target₹5,983.6015.6% upside · 20 analysts8%+ upside

Questions about ALKEM

What is the share price of Alkem Laboratories Limited (ALKEM) today?

ALKEM last traded at ₹5,175.00 (+0.76% on the day) on the NSE. Its 52-week range is ₹4,811.00 to ₹5,933.50. Prices are delayed and come from Yahoo Finance.

Is ALKEM a good stock for the long term?

StockLens rates ALKEM 5.7 out of 10 (Average) overall. Its long-term verdict is "Neutral (watchlist)": A mixed picture. Wait for better value or a clearer trend. Strengths: cheap vs peers, low debt, high margins. Concerns: bearish moving averages, downtrend, falling profits.

Is ALKEM share overvalued?

ALKEM trades at a P/E of 29.9 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 4.16.

Is ALKEM good for short-term trading?

The trade bias for the next few weeks is "Strong short": Trend and momentum are clearly pointing down. The price is 4.4% below its 200-day average and 14-day RSI is 49.

Which stocks are similar to ALKEM?

Similar Pharma & Healthcare stocks of comparable size include Biocon, Glenmark Pharmaceuticals, Lupin, Max Healthcare, Aurobindo Pharma. You can compare up to 4 of them side by side on StockLens.

About Alkem Laboratories Limited

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti – infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology, central nervous system, anti-diabetic, iron deficiency, pain management, and urology, as well as vitamins, minerals, and nutrients. It also provides cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. Alkem Laboratories Limited was incorporated in 1973 and is based in Mumbai, India.

Stocks similar to ALKEM

Compare ALKEM with BIOCON, GLENMARK, LUPIN

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.